ic9-car19 cells
Cell therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT03016377)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ic9-car19 cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03696784 | Phase 1 | Mar 12, 2019 | Bellicum Pharmaceuticals, University of North Carolina at Chapel Hill, V Foundation |
| NCT03016377 | Phase 1 | Jun 1, 2017 | University of North Carolina at Chapel Hill |
| NCT03594162 | N/A | — | Bellicum Pharmaceuticals, University of North Carolina at Chapel Hill |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of North Carolina at Chapel Hill | Academic/Hospital | 3 | 3 | 2 | 2017 |
| Bellicum Pharmaceuticals | For profit | 2 | 0 | 2 | 2019 |
| V Foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1